In consistence with our study, Loriot and colleagues developed a novel BCL-2 and BCL2L1 inhibitor S44563 and found that it showed radiosensitization in small-cell lung cancer (Loriot et al, 2014). Here, BCL2 is linked to small cell lung carcinoma.